Vif and Apobec3G in the innate immune response to HIV: a tale of two proteins.
It is now 26 years after the first published report on HIV, and the global epidemic continues unabated, with estimates of over 33 million people currently infected, worldwide. Development of targeted therapies aimed at perturbing the HIV life cycle can be achieved only with a detailed comprehension of the dynamics of virus-host interactions within the cell. One such critical virus-host interaction is the recently elucidated interplay between the viral Vif protein and the innate immune defense molecule Apobec3G. Apobec3G potently suppresses HIV replication, but Vif can alleviate this inhibition, rescuing viral infectivity. Early work describing the characterization of Vif and the cloning and identification of Apobec3G as an antiviral are discussed. Recent advances detailing the mechanisms of the Vif-Apobec3G regulatory circuit and our nascent understanding of Apobec3G endogenous function are also presented. Collectively, these studies have shed light on potential novel therapeutic strategies aimed at exploiting Apobec3G antiviral function to abrogate HIV replication.
Farrow
Melissa A
MA
College of the Holy Cross, Department of Biology, 1 College Street, Worcester, MA 01610, USA. mfarrow@holycross.edu
Sheehy
Ann M
AM
D000071480:APOBEC-3G Deaminase; D003564:Cytidine Deaminase / Q000378:metabolism*; D006678:HIV / Q000276:immunology / Q000378:metabolism*; D015658:HIV Infections / Q000378:metabolism* / Q000821:virology; D006801:Humans; D007113:Immunity, Innate; D008954:Models, Biological; D054320:vif Gene Products, Human Immunodeficiency Virus / Q000378:metabolism*
D054320:vif Gene Products, Human Immunodeficiency Virus; D000071480:APOBEC-3G Deaminase; C464924:APOBEC3G protein, human; D003564:Cytidine Deaminase